Tesamorelin 5mg + Ipamorelin 5mg Dosage Chart
Tesamorelin is dosed at 125 mcg–1 mg daily by subcutaneous injection in educational protocols, typically at night. A 10mg blend reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
- Reconstitute: Add 3.0 mL bacteriostatic water to the 10 mg vial → ~3.33 mg/mL total (1.67 mg/mL each peptide).
- Typical daily range: 250–2000 mcg tesamorelin + 125–1000 mcg ipamorelin (gradual titration).
- Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 16.7 mcg of each peptide on a U‑100 insulin syringe.
- Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); after reconstitution, use immediately or refrigerate and use within 24–48 hours[5].
This blend combines tesamorelin, a synthetic GHRH analog, with ipamorelin, a selective ghrelin mimetic (growth hormone secretagogue). When administered together, GHRH analogs and ghrelin mimetics produce synergistic GH pulses[1][2]. The FDA‑approved tesamorelin dose is 2 mg SC daily[3], while ipamorelin is commonly studied at 100–300 mcg SC daily[4]. This educational protocol presents a once‑daily subcutaneous approach with gradual titration using a 1:1 blend ratio.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
| Week | Tesamorelin Dose | Ipamorelin Dose | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 125 mcg (0.125 mg) | 23 units (0.23 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 250 mcg (0.25 mg) | 45 units (0.45 mL) |
| Weeks 5–6 | 1000 mcg (1.0 mg) | 500 mcg (0.5 mg) | 90 units (0.90 mL) |
| Weeks 7–10 | 1500 mcg (1.5 mg) | 750 mcg (0.75 mg) | 135 units (1.35 mL) |
| Weeks 11–16 | 2000 mcg (2.0 mg) | 1000 mcg (1.0 mg) | 180 units (1.80 mL) |
Route: Subcutaneous (SC) | Frequency: Once daily
Note: The 1:1 blend ratio means tesamorelin and ipamorelin are present in equal amounts per mL. At 3.0 mL reconstitution: 1 mL = 1.67 mg tesamorelin + 1.67 mg ipamorelin. Higher‑volume injections (≥1.0 mL) may be split across two sites if preferred for comfort.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 24–48 hours[5].
Plan based on an 8–16 week daily protocol with gradual titration.
- Peptide Vials (Tesamorelin 5 mg + Ipamorelin 5 mg, 10 mg blend each):
- 8 weeks ≈ 10 vials
- 12 weeks ≈ 19 vials
- 16 weeks ≈ 31 vials
- Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- 12 weeks (19 vials): 57 mL → 6 × 10 mL bottles
- 16 weeks (31 vials): 93 mL → 10 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Protocol Overview
Concise summary of the once‑daily regimen.
- Goal: Support pulsatile GH release through dual GHRH + ghrelin pathway stimulation[1][2].
- Schedule: Daily subcutaneous injections for 8–16 weeks.
- Dose Range: Tesamorelin 250–2000 mcg + ipamorelin 125–1000 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
- Storage: Lyophilized refrigerated 2–8 °C; reconstituted use immediately or within 24–48 hours.
Dosing Protocol
Suggested daily titration approach.
- Start: 250 mcg tesamorelin + 125 mcg ipamorelin daily; increase every 2 weeks.
- Target: 1500–2000 mcg tesamorelin + 750–1000 mcg ipamorelin by Weeks 7–16.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–16 weeks.
- Timing: Evening or bedtime administration may align with natural GH secretion patterns[4]; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F) in dry, dark conditions; may be kept at ≤25 °C (77 °F) up to 3 months after dispensing[5].
- Reconstituted: Inject immediately after reconstitution; if stored, refrigerate and use within 24–48 hours; do not freeze[5].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[5][6].
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Higher‑volume injections (≥1.0 mL) may be split between two sites for comfort.
Tesamorelin is a synthetic 44‑amino‑acid GHRH analog that stimulates pituitary GH release[3]. Ipamorelin is a pentapeptide ghrelin mimetic that acts on the GHS‑R1a receptor, selectively stimulating GH secretion without significantly affecting cortisol, prolactin, or ACTH[4][7]. Combined GHRH + GHRP/ghrelin‑mimetic administration produces synergistic, amplified GH pulses compared to either agent alone[1][2]. Human pharmacokinetic studies show ipamorelin achieves peak GH release approximately 40 minutes post‑dose[8].
Observations from preclinical and clinical literature.
- Enhanced pulsatile GH secretion through dual‑pathway stimulation[1][2].
- Tesamorelin (2 mg/day) demonstrated reductions in trunk fat and visceral adipose tissue in HIV‑associated lipodystrophy trials[3][9].
- Ipamorelin shows high GH selectivity with minimal impact on cortisol or other hormones[4][7].
- Common adverse events with tesamorelin include injection‑site reactions (erythema, pruritus), arthralgia, and peripheral edema[5][9].
- Ipamorelin is generally well tolerated; transient flushing or headache may occur[7].
Complementary strategies for best outcomes.
- Pair with a balanced, protein‑forward diet tailored to energy needs.
- Combine resistance training and aerobic activity to reinforce metabolic adaptations.
- Prioritize sleep and stress management to support adherence and recovery.
- Evening dosing may align with natural nocturnal GH secretion patterns.
General subcutaneous guidance from clinical best‑practice resources[6].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[5][11].
Recommended Source
We recommend Pure Lab Peptides for high‑purity Tesamorelin 5 mg + Ipamorelin 5 mg (10 mg Blend).
Why Pure Lab Peptides?
- High‑purity, third‑party‑tested lots with batch COAs.
- Consistent, ISO‑aligned handling and documentation.
- Reliable fulfillment to maintain cold‑chain integrity.
Important Note
This content is for educational purposes only and is not medical advice.
References
-
PMC — The Safety and Efficacy of Growth Hormone Secretagogues— GHRH + GHRP synergy; dual pathway GH stimulation mechanisms
-
Endocrine Reviews — Growth Hormone Secretagogues— Synergistic amplification of GH release with combined GHRH and ghrelin mimetics
-
NCBI LiverTox — Tesamorelin— Synthetic GHRH analog; recommended dose 2 mg SC daily for HIV lipodystrophy
-
PubMed — Ipamorelin, the first selective growth hormone secretagogue— High GH potency and selectivity; no cortisol/ACTH effect
-
FDA Egrifta (tesamorelin) Label— SC abdomen injection; rotate sites; storage and reconstitution guidance
-
CDC — Vaccine Administration: Subcutaneous Injection— Subcutaneous injection technique (45° angle, pinch skin, no aspiration)
-
European Journal of Endocrinology — Ipamorelin GH selectivity— Potent and specific GH release without affecting cortisol, prolactin, or FSH/LH
-
PubMed — Pharmacokinetic-pharmacodynamic modeling of ipamorelin— Human GH release peaked ~0.67 h post-dose
-
JAMA — Tesamorelin for Abdominal Fat in HIV— Phase 3 trials demonstrating visceral fat reduction with tesamorelin
-
CDC — Vaccine Administration During— General subcutaneous route guidance (angle/site)
-
NCBI Bookshelf — Best Practices for Injection— Asepsis, preparation, and administration guidance
-
PMC — Subcutaneous Drug Injection Review— Pharmacologic considerations of the subcutaneous route
-
Drugs — Tesamorelin: A Review— Comprehensive review of tesamorelin pharmacology and clinical use
-
Pure Lab Peptides— Tesamorelin 5 mg + Ipamorelin 5 mg (10 mg Blend) product page